Annexon Q4 2024 Earnings Report $2.53 -0.13 (-4.89%) As of 03/13/2025 04:00 PM Eastern Earnings HistoryForecast Annexon EPS ResultsActual EPS-$0.33Consensus EPS -$0.28Beat/MissMissed by -$0.05One Year Ago EPSN/AAnnexon Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAnnexon Announcement DetailsQuarterQ4 2024Date3/3/2025TimeBefore Market OpensConference Call ResourcesANNX Earnings History Remove Ads Annexon Earnings HeadlinesBank of America Securities Remains a Buy on Annexon Biosciences (ANNX)March 10, 2025 | markets.businessinsider.comAnnexon price target lowered to $11 from $12 at BofAMarch 10, 2025 | markets.businessinsider.comMusk’s real agenda in D.C. In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of America…March 14, 2025 | Porter & Company (Ad)What is HC Wainwright's Forecast for Annexon Q1 Earnings?March 8, 2025 | americanbankingnews.comCantor Fitzgerald Decreases Earnings Estimates for AnnexonMarch 7, 2025 | americanbankingnews.comNeedham & Company LLC Reaffirms "Buy" Rating for Annexon (NASDAQ:ANNX)March 6, 2025 | americanbankingnews.comSee More Annexon Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Annexon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annexon and other key companies, straight to your email. Email Address About AnnexonAnnexon (NASDAQ:ANNX), a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.View Annexon ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles These 3 Q1 Earnings Winners Will Go HigherAnalysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before Earnings Upcoming Earnings PDD (3/19/2025)Micron Technology (3/20/2025)Accenture (3/20/2025)FedEx (3/20/2025)NIKE (3/20/2025)Cintas (3/26/2025)Paychex (4/1/2025)Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
